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Background: Type 2 diabetes is an endocrine disorder that affects a large percentage of patients. High blood
glucose causes fatty deposits in the liver which is likely to increase in SGOT and SGPT activities. Significant increase
in SGOT/SGPT and low HDL levels is observed in patients with diabetes. Serum fructosamine concentration reflects
the degree of blood glucose control in diabetic patients. This study was aimed to investigate the antidiabetic,
hypolipidemic and hepatoprotective effects of supplementation of Boswellia serrata in type2 diabetic patients.
Methods: 60 type 2 diabetic patients from both sexes (30 males and 30 females) were dedicated to the control
and intervention groups (30 subjects per group). Boswellia serrata gum resin in amount of 900 mg daily for 6 weeks
were orally administered (as three 300 mg doses) in intervention group and the control group did not receive
anything. Blood samples were taken at the beginning of the study and after 6 weeks. Blood levels of fructosamine,
lipid profiles as well as hepatic enzyme in type 2 diabetic patients were measured.
Results: Treatment of diabetic patient with Boswellia serrata was caused to significant increase in blood HDL levels
as well as a remarkable decrease in cholesterol, LDL, fructosamine (p < 0.05) SGPT and SGOT levels after 6 weeks
(p < 0.01). In spite of reduction of serum triglyceride, VLDL levels in intervention group, we did not detect a
significant difference after 6 weeks.
Conclusion: This study showed that Boswellia serrata supplementation can be beneficial in controlling blood
parameters in patients with type 2 diabetes. Therefore, its use can be useful in patients with medicines.
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Type 2 diabetes is one of the most serious endocrine dis-
orders in worldwide [1]. It has predicted that the diabetes
prevalence among the people, would reach to 552 million
populations in year 2030 [2]. resistance to insulin as well
as increase in generation of reactive oxygen species
(ROS) and oxidative stress which result in destruction of
insulin producing β-cells in pancreatic tissue, have crit-
ical roles in mechanism of induction of diabetes [3,4].
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article, unless otherwise stated.hyperglycemic conditions in the blood [5] and on the
other hand the control of blood glucose in diabetic
patients is poor in Iran like many other countries [6]. At
the present, the current methods for cure of diabetes
include exercise, diet, and the use of oral hypoglycemic
agents as well as insulin therapy. However, chemical an-
tidiabetic drugs such as biguanides and sulphonylureas
have different side effects which include hypoglycemia,
hepatotoxicity, and hypercoagulability [7]. In the recent
years, there has been a tendency to use of medicinal
plants because of the lower side effects and variety of ef-
fective compounds in plants, and especially the recom-
mends by the World Health Organization (WHO) to
use of medicinal plants [8]. Boswellia serrata is a plant
species of Burseraceae family which grows in differententral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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rata gum is Boswellic acids which are grups of pentacyclic
terpenoids [10]. This gum has been used for many years in
traditional medicine of India, china and Greek in treatment
of respiratory disorders, gastric diseases and joint inflam-
mation [9]. Its adverse effects in human are very low and
ignorable and there has not been any report about serious
interference of it with other drugs [11]. Different investiga-
tors have indicated to hypoglycemic effects of Boswellia
[12]. In an animal study, a plant formulation of contain
Boswellia, caused to beneficial effects in blood glucose
reduction of STZ induced diabetic rats which its effect is
comparable with fenformine [13]. In several animal studies,
it is attributed to the antioxidant properties of Boswellia
serrata extract [14]. In study of Pandey et al. has been
shown that Boswellia serrata gum resins extract caused to
reduce serum cholesterol and increase of HDL in rats [15].
Our previous study showed that 6 weeks supplementation
of Boswellia serrata to type 2 diabetic patients, resulted in
remarkably decrease in fasting blood glucose and increase
in insulin level [16]. However, as far as we are aware, no
studies have been reported on hypolipidemic effects of Bos-
wellia serrata and its effect on SGPT level in human, the
present study was performed to evaluate the effect of sup-
plementation of Boswellia serrata on these factors among
type2 diabetic patients.Materials and methods
The present study as clinical trial was performed in
Endocrinology and Diabetes clinic of Ahvaz Jundishapur
University of Medical Sciences in Iran, in 2012 (IRCT2
01112258515N1). The research was approved by Med-
ical Ethical Committee of the Ahvaz University by the
identification code of (eth299).
The number of samples was obtained according to the






of α = %/05 and test power of %90 [17].
For perform of this investigation, an entry and exit criteria
was considered for all participant subjects Inclusion criteria
to study were 1) type 2 diabetic individuals suffering over 4
years. 2) Fasting blood glucose in range of 140–250 mg/dl 3)
age range between 30–48 years. Exclusion criteria were those
patients that have Hepatic cirrhosis, Chronic Kidney Disease
(CKD), active Proliferative Diabetic Retinopathy (PDR), Con-
gestive Heart Failure (CHF), Myocardial Infarction (MI) in
recent 6 month, pregnant and lactating women [18]. After
elucidation the aim of present investigation, 60 patients were
declared their satisfaction to participate in this study and so
written consent was taken from all of them. Then all individ-
uals were randomly divided into two groups; test and control
groups (30 in each group). Test individuals group received
solid form of Boswellia serrata gum resin 900 milligram dailywhich were divided in three 300 mg doses for 6 weeks and
control group have not received anything. Boswellia serrata
was bought from the reliable local markets of Ahvaz city.
Boswellia serrata is maintained in herbarium section of
department of Botany of Ahvaz Jundishapur University and
was scientifically confirmed by this department. It should be
mentioned that all participant in this research have alone
used oral hypoglycemic agents include GIyburide, Acarbose,
Metformin and …, which didn’t changed in the type and
dose of drugs during the study period. During the study,
weekly telephone contacts were established with the pa-
tients and they reply the questions about any side effects
such as nausea and reflux and serious drug interactions
with other drugs. Also they were recommended in associ-
ation with regular consumption of Boswellia serrata gum
resin. Patients had their routine diet and physical activity
levels until the end of the study. Demographic informa-
tion's including weight, body mass index (BMI), Systolic
and Diastolic pressure were measured at the beginning
and end of the study. At the beginning of the study and
after 6 weeks, venous blood samples were taken from all
patients and were centrifuged at 3500 rpm for about
20 min for obtaining serum. Serum could be kept in −70°C
refrigerator until evaluation. After serum separation, some
biochemical factors include: Triglycerides, Total choles-
terol, HDL, SGPT, SGOT were assessed in method of cal-
orimetric enzymatic using commercial kits (pars azmoon,
Iran), and Fructosamine (using Diazyme kit, USA). Very
low-density lipoprotein cholesterol (VLDL) equals one-
fifth of Triglycerides amount. For calculation the content
of low density lipoprotein cholesterol (LDL), the sum of
HDL and VLDL amount is subtracted from total choles-
terol content and the remainder is LDL.
Data are expressed by SPSS as mean ± SEM. For this
process, we used Paired t-test method for assessment blood
parameter of before and after consumption of Boswellia
serrata. Also we used the method of independent t-test for
data analysis between two groups. P < 0.05 was considered
as statistically significant difference.
Results
In this study, 50 percent of participants were male and 50
percent were female. The average of age in Boswellia
group and control group was between 30–48 years. In the
beginning of study, there were not remarkable differences
in means of measured factors in body and blood between
the Boswellia and control groups (Table 1). After 6 weeks
consuming of Boswellia, we were observed significant
increase in blood HDL level and remarkable decrease
in blood cholesterol, LDL, fructosamine (p < 0.05) SGPT
(p < 0.001) and SGOT (p < 0.01) levels of patients. There
were no significant difference in serum triglyceride and
VLDL levels of patients (Table 2). In control group, HDL
level was significantly increased after 6 weeks (p < 0.01).
Table 1 The comparison of means of demographic
informations and biochemical index of basal between
groups
Variables Control group Boswellia group P value
Weight (Kg) 71 ± 3.3 68 ± 4.09 0.53
BMI (m2/Kg) 26.87 ± 4.1 25.93 ± 1.2 0.68
Systolic pressure (mmHg) 120.52 ± 1.3 118.88 ± 4.2 0.76
Diastolic pressure (mmHg) 76.31 ± 2.19 75.55 ± 2.9 0.84
HDL (mg/dl) 32.37 ± 2.42 35.07 ± 2.33 0.428
LDL (mg/dl) 103.59 ± 6.02 103.87 ± 6.01 0.975
VLDL (mg/dl) 38.77 ± 5.2 29.14 ± 4.22 0.149
TG (mg/dl) 194.33 ± 26.06 145.07 ± 21.07 0.144
Total Cholesterol (mg/dl) 174.79 ± 5.03 168.03 ± 7.48 0.458
SGPT (IU/L) 35 ± 4.64 32.64 ± 2.75 0.654
SGOT (IU/L) 29.107 ± 3.13 31.54 ± 3 0.58
Fructosamine (μM/L) 407.73 ± 24.39 405.78 ± 19.03 0.906
Table 3 The comparison of means of baseline and after 6
weeks biochemical index in control group
Variables Baseline End 6 weeks P value
HDL (mg/dl) 32.37 ± 2.42 41.66 ± 2.54 <0.01
LDL(mg/dl) 103.59 ± 6.02 110.07 ± 9.11 >0.05
VLDL (mg/dl) 38.87 ± 5.2 34.37 ± 3.34 >0.05
TG (mg/dl) 194.33 ± 26.03 171.95 ± 16.72 >0.05
Total Cholesterol (mg/dl) 174.79 ± 5.03 183.83 ± 9.42 >0.05
SGPT (IU/L) 35 ± 4.64 30.42 ± 3.2 >0.05
SGOT (IU/L) 31.54 ± 3 28.79 ± 3.18 >0.05
Fructosamine(μM/L) 407.73 ± 24.86 398.95 ± 18.82 >0.05
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variables at the end of study in control group (Table 3).
Comparison between blood parameters of control and
Boswellia groups after 6 weeks, showed significant de-
crease in the levels of VLDL and TG (p < 0.05) as well as
total cholesterol and SGOT levels (p < 0.01) in Boswelia
group rather than control group (Table 4). During the
study, have not observed any side effects such as nausea
and reflux, . . . and there were no reports about serious
drug interactions with other drugs.Discussion
In spite of several treatment options for type 2 diabetes
diseases, and on the other hand, lack of definitive cure
for it, more investigations are needed for treatment this
disease [19]. This study evaluates the efficiency of long-
term consumption of Boswellia serrata on glycaemic and
lipid profiles in patients with type 2 diabetes. Our study
indicates that supplementation of Boswellia serrata in
three 300 mg doses daily for 6 weeks, significantlyTable 2 The comparison of means of biochemical index in
baseline and after intervention in Boswellia group
Variables Baseline End 6 weeks P value
HDL (mg/dl) 35.07 ± 2.33 40.39 ± 1.88 <0.05
LDL(mg/dl) 103.87 ± 6.01 88.39 ± 6.7 <0.05
VLDL (mg/dl) 29.14 ± 4.22 25.08 ± 2.36 >0.05
TG(mg/dl) 145.07 ± 21.07 129.35 ± 11.87 >0.05
Total Cholesterol(mg/dl) 168.03 ± 7.48 153.82 ± 5.89 <0.05
SGPT (IU/L) 32.64 ± 2.75 23.36 ± 1.78 <0.001
SGOT (IU/L) 29.107 ± 3.13 18.75 ± 2.12 <0.01
Fructosamine(μM/L) 405.78 ± 19.03 383.31 ± 16.41 <0.05improves HDL, LDL and total cholesterol levels and
serum SGPT, SGOT in type2 diabetic patients. Also in
the present study, supplementation of diabetic patients
with Boswellia serrata is reduced fructosamine level. Be-
cause the concentration of glucose is normally used to
detect blood glucose control in diabetic patients, it
seems that fructosamine is more useful why that used to
show the decline and improve diabetic conditions over a
period of several days or weeks [20]. Fructosamine is a
measurement putative of glycosylated proteins and it has
been suggested to measure blood value as a method for
evaluating diabetes mellitus [21]. According to Elgawish
study, those agents that have free radical scavenging or
antioxidant properties, may help prevent oxidative reac-
tions associated with protein glycosylation [22]. Several
researchers have indicated to antioxidant effect of differ-
ent membrane of Boswellia species [23,24]. On the other
hand, a decrease in blood glucose levels may have also
contributed to decreased levels of glycated proteins in
diabetic patients' supplementated with Boswellia serrata.
This finding is in accordance with our previous study
which showed that Boswellia serrata supplementation in
diabetic patients caused to significant decrease in fasting
blood glucose level [17]. Also Awadi et al. in an animal
study showed that, a plant formulation containing BoswelliaTable 4 The comparison of means of demographic
information and biochemical index after 6 weeks
between groups
Variables Control group Boswellia group P value
HDL (mg/dl) 41.66 ± 2.54 40.39 ± 1.88 >0.05
LDL(mg/dl) 110.07 ± 9.11 88.39 ± 6.7 >0.05
VLDL(mg/dl) 34.37 ± 3.34 25.08 ± 2.36 <0.05
TG (mg/dl) 171.95 ± 16.72 129.35 ± 11.87 <0.05
Total Cholesterol (mg/dl) 183.83 ± 9.42 153.82 ± 5.89 <0.01
SGPT (IU/L) 30.42 ± 3.2 23.36 ± 1.78 >0.05
SGOT (IU/L) 28.79 ± 3.18 18.75 ± 2.12 <0.01
Fructosamine(μM/L) 398.95 ± 18.82 383.31 ± 16.41 >0.05
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diabetic rats [12]. For that reason, likely, Boswellia serrata
with its free radical scavenging and blood glucose lowering
potential, effectively reduces the formation of glycated
proteins. Safayhi et al. reported that boswellic acids (the
main component of Boswellia serrata) causes to hepatopro-
tection against galactosamine/endotoxin-induced toxicity in
mice [25]. Also Jyothi study showed that Boswellia serrata
oleo-gum resin can reduce liver injury caused by chemicals.
[26]. As evidenced by a reduction in SGPT and SGOT
among type 2 diabetic patients supplemented by Boswellia
serrata, our study demonstrate that Boswellia serrata is pos-
sess partial positive hepatoprotective effect. Pandey et al.
reported that Boswellia serrata oleo gum is able to decrease
the production of nitric oxide [18]. It is shown that those
components that are reducing the production of NO in
the liver tissue possess liver protective effects [27]. Likely
Boswellia serrata, through reduction of NO generation,
can protect the liver function. This research showed that
Boswellia serrata supplementation has beneficial effect in
augmentation of HDL and reduction of total cholesterol
and LDL levels among type2 diabetic patients. In agree-
ment with our results, Pandey et al. indicated to hypo-
cholesterolemia effect of gum resins extract of Boswellia
in rats [15]. In diabetes, insulin deficiency is result in
enhancement of plasma FFA concentration because of
FFA explosion from body fat stores as a result of increase
in lipolysis cycle due to insulin deficiency [28]. Likely
Boswellia serrata supplementation restores β-cells func-
tion for insulin secretion in diabetic patients and so they
will be compensated insulin deficiency. On the other
hand, Insulin helps to reduce serum lipid profiles. How-
ever in spite of distinctive improvement of serum trigly-
ceride and VLDL levels of type2 diabetic patients after
supplementation with Boswellia serrata in our study, sig-
nificant difference in our study did not detect varying
levels after 6 weeks. The full duration of the clinical trial,
as well as the lack of precise control of diet, exercise and
patient education associated with diabetes who partici-
pated in our study from other sources (except physicians)
to be taken. May be grounds for non-significant differ-
ences in the factors mentioned can cause in type 2
diabetes.Conclusion
In conclusion, the suggested health benefits of Boswellia
serrata supplementation in type2 diabetic patients could
ameliorate some of biochemical factor levels. Daily con-
sumption of 900 mg of Boswellia serrata possible depicts a
safe and effective means to decrease the risk factors asso-
ciated with type2 diabetic subjects. If diabetes subjects use
Boswellia serrata in their food regularly, they may main-
tain their Fructosamine levels, hepatic enzyme activitiesand lipid profiles close to normal levels. However, more
extensive pharmacological experiments are required.
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